Jordana Jampel

DocwireNews

A two-sample Mendelian randomized analysis was performed to determine the effects of anti-CD20 antibodies on the occurrence and progression of endometrial cancer.The research group, led by Jinqui Su, collected data of MS4A1 single nucleotide polymorphism encoding gene of CD20 from the genome-wide association study (GWAS) and performed a drug target Mendelian randomization analysis to detect the causal relationship between anti-CD20 antibody and the risk for endometrial cancer. The risk for follicular lymphoma was used as a positive control, and endometrial cancer was used as the outcome.Results<ul>
<li>Endometrial cancer exerted an effect on 28 immunophenotypes, predominantly on CD20; CD20 expression increased in immunoglobulin D+ CD38- B cells, memory B cells, and unswitched memory B cells increased after endometrial cancer onset.</li>
<li>The researchers detected one immunophenotype that specifically exerted a dangerous effect on endometrial cancer: CD3/TD CD4+ (mature stage of the T-cell group).</li>
<li>CD20 could be used as both a risk factor and protective factor for endometrial cancer (P&gt;.05).</li>
<li>Anti-CD20 antibodies significantly reduced the risk for follicular lymphoma, including two GWAS pooled datasets.</li>
<li>Anti-CD20 antibodies exerted a protective effect on endometrial cancer in two GWAS pooled datasets (P&gt;.05).</li>
</ul>These results confirm the close relationship between CD20 protein and endometrial cancer: Anti-CD20 antibodies exert a protective effect on endometrial cancer and reduce the risk for disease morbidity, thus providing a potential reference for future clinical diagnosis and treatment. Further clinical verification of these results is warranted, the researchers noted.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

B-Cell Protein Has Both Risk and Protective Factors in Endometrial Cancer

Gynecologic Cancer

A Mendelian randomized analysis was performed to determine the effects of anti-CD20 antibodies on endometrial cancer.

B-Cell Protein Has Both Risk and Protective Factors in Endometrial Cancer 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe